Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report
- 1 March 2001
- journal article
- case report
- Published by Elsevier in Gastroenterology
- Vol. 120 (4) , 995-999
- https://doi.org/10.1053/gast.2001.22556
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Behçet's DiseaseNew England Journal of Medicine, 1999
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Intestinal Behçet's Disease: A Case Report and Review of Japanese Reports in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's diseaseThe Lancet, 1997
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- A New Measure of Health Status for Clinical Trials in Inflammatory Bowel DiseaseGastroenterology, 1989
- Differential Diagnosis of Ulcerative Colitis and Crohn’s Ileocolitis and Other Specific Inflammatory Disease of the BowelMedical Clinics of North America, 1980
- Development of a Crohn's Disease Activity IndexGastroenterology, 1976